Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
Open Access
- 14 October 2011
- journal article
- research article
- Published by Elsevier
- Vol. 147 (2) , 306-319
- https://doi.org/10.1016/j.cell.2011.08.046
Abstract
No abstract availableFunding Information
- University of Chicago
- Canadian Institutes of Health Research (MOP-6849)
- National Institutes of Health (R01-GM72688, R21-CA132700, T32GM07281, RR-15301)
- European Molecular Biology Organization (ASTF 293.00-2009)
- U.S. Department of Energy (DE-AC02-06CH11357)
This publication has 49 references indexed in Scilit:
- A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domainNature Structural & Molecular Biology, 2010
- Stat5 is indispensable for the maintenance of bcr/abl ‐positive leukaemiaEMBO Molecular Medicine, 2010
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitorsNature, 2010
- SH2 domains: modulators of nonreceptor tyrosine kinase activityCurrent Opinion in Structural Biology, 2009
- Structural Coupling of SH2-Kinase Domains Links Fes and Abl Substrate Recognition and Kinase ActivationCell, 2008
- Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and DasatinibJournal of Biological Chemistry, 2008
- Supercharging Proteins Can Impart Unusual ResilienceJournal of the American Chemical Society, 2007
- MolProbity: all-atom contacts and structure validation for proteins and nucleic acidsNucleic Acids Research, 2007
- High-affinity single-domain binding proteins with a binary-code interfaceProceedings of the National Academy of Sciences, 2007
- [6] Efficient site-directed mutagenesis using uracil-containing DNAPublished by Elsevier ,1991